Patents by Inventor Kelly M. Lager
Kelly M. Lager has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10729756Abstract: Multiple DIVA vaccines effective against porcine reproductive and respiratory syndrome virus (PRRSV) are disclosed. The DIVA vaccines may be negative DIVAs or positive DIVAs. The DIVA vaccines may be produced by modifying the nsp2 region of a modified live virus vaccine. The modification may be one or more deletions only (negative DIVAs) or a deletion with an insertion (positive DIVAs). The insertion may be of an epitope tag, such as a V5, S-Tag, or FLAG tag. Produced DIVA vaccines may be stable through multiple passes and thus may be effective for production and vaccination of animals.Type: GrantFiled: May 25, 2018Date of Patent: August 4, 2020Assignee: The United States of America, as represented by the Secretary of AgricultureInventors: Kay S. Faaberg, Allyn Spear, Matthew A. Kappes, Kelly M. Lager
-
Patent number: 10543268Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: September 10, 2018Date of Patent: January 28, 2020Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as Represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20180369363Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: September 10, 2018Publication date: December 27, 2018Applicants: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20180344837Abstract: Multiple DIVA vaccines effective against porcine reproductive and respiratory syndrome virus (PRRSV) are disclosed. The DIVA vaccines may be negative DIVAs or positive DIVAs. The DIVA vaccines may be produced by modifying the nsp2 region of a modified live virus vaccine. The modification may be one or more deletions only (negative DIVAs) or a deletion with an insertion (positive DIVAs). The insertion may be of an epitope tag, such as a V5, S-Tag, or FLAG tag. Produced DIVA vaccines may be stable through multiple passes and thus may be effective for production and vaccination of animals.Type: ApplicationFiled: May 25, 2018Publication date: December 6, 2018Inventors: Kay S. Faaberg, Allyn Spear, Matthew A. Kappes, Kelly M. Lager
-
Patent number: 10098945Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: December 12, 2016Date of Patent: October 16, 2018Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20170151324Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: December 12, 2016Publication date: June 1, 2017Applicants: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 9549975Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: March 3, 2015Date of Patent: January 24, 2017Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as Represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20150273049Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: March 3, 2015Publication date: October 1, 2015Applicants: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, As Represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 8999352Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: November 23, 2011Date of Patent: April 7, 2015Assignees: Icahn School of Medicine at Mount Sinai, St. Jude Children's Research Hospital, The United States of America, as represented by the Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20130034581Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: November 23, 2011Publication date: February 7, 2013Inventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 8124101Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: GrantFiled: June 1, 2005Date of Patent: February 28, 2012Assignees: Mount Sinai School of Medicine, St. Jude Children's Research Hospital, The United States of America as represented by The Secretary of AgricultureInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Publication number: 20090010962Abstract: The present invention relates, in general, to attenuated swine influenza viruses having an impaired ability to antagonize the cellular interferon (IFN) response, and the use of such attenuated viruses in vaccine and pharmaceutical formulations. In particular, the invention relates to attenuated swine influenza viruses having modifications to a swine NS1 gene that diminish or eliminate the ability of the NS1 gene product to antagonize the cellular IFN response. These viruses replicate in vivo, but demonstrate decreased replication, virulence and increased attenuation, and therefore are well suited for use in live virus vaccines, and pharmaceutical formulations.Type: ApplicationFiled: June 1, 2005Publication date: January 8, 2009Applicants: MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, THE UNITED STATED OF AMERICA AS REPRESENTED BY THE SECRETARY OF AGRICULTUREInventors: Peter Palese, Adolfo Garcia-Sastre, Richard J. Webby, Juergen A. Richt, Robert G. Webster, Kelly M. Lager
-
Patent number: 6015663Abstract: A test based on restriction enzyme analysis identifies and differentiates strains of porcine reproductive and respiratory syndrome virus (PRRSV). Amplified cDNA from the ORF 5 region of the viral genome has been targeted for identification of unique restriction sites that allow for the differentiation of the vaccine strain from field strains, and for differentiation of field strains from each other through the use of selected restriction enzymes. This assay is useful for both clinical diagnosis of PRRSV field strains in vaccinated pigs as well as for epidemiological studies in the evaluation of the source and transmission of PRRS field viruses.Type: GrantFiled: March 1, 1996Date of Patent: January 18, 2000Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Ronald D. Wesley, Deborah F. Clouser, William L. Mengeling, Vladimir G. Andreyev, Ann C. Vorwald, Kelly M. Lager
-
Patent number: 5976537Abstract: Vaccines against porcine reproductive and respiratory syndrome (PRRS) have been produced by attenuation of wild type strains of the virus selected from the group of attenuated NADC-8, attenuated NADC-9 and attenuated NVSL-14. These vaccines are useful in monovalent, bivalent or polyvalent vaccines.Type: GrantFiled: July 2, 1996Date of Patent: November 2, 1999Assignee: The United States of America as represented by the Secretary of AgricultureInventors: William L. Mengeling, Kelly M. Lager, Ann C. Vorwald